Phosphatidylserine Supplement Improves Liver Health and Blood Sugar Control in Mice

This groundbreaking study reveals that phosphatidylserine supplementation offers dual benefits for liver health and metabolic control, potentially addressing two major health challenges simultaneously. Fatty liver disease affects millions worldwide and often progresses alongside diabetes, creating a dangerous cycle of metabolic dysfunction.

Researchers used the MUP-uPA mouse model to study both early fatty liver disease and advanced metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis. Mice received dietary phosphatidylserine supplementation while researchers monitored liver function, blood glucose control, and cellular metabolism across multiple tissues.

The results were remarkable: PS supplementation reduced liver triglyceride accumulation, inflammation, and fibrosis in mice with MASH. Simultaneously, both male and female mice showed improved glucose control and insulin sensitivity. Most intriguingly, these benefits occurred despite suppressed glycolysis and glucose oxidation, indicating PS works through alternative metabolic pathways.

Metabolic analysis revealed that PS shifted fuel utilization toward fat metabolism, particularly in muscle tissue. This metabolic flexibility enhancement was accompanied by improved mitochondrial function and oxidative capacity, suggesting PS helps cells become more efficient energy producers. The supplement also enhanced insulin signaling in both muscle and liver tissues.

For longevity and health optimization, these findings suggest PS supplementation could address multiple aspects of metabolic syndrome simultaneously. By improving liver health while enhancing metabolic flexibility, PS may help prevent the progression from fatty liver to more serious liver disease while maintaining healthy blood sugar levels.

However, this research was conducted in mice, and human studies are needed to confirm these benefits and establish optimal dosing protocols for therapeutic use.